Literature DB >> 24389118

Distribution of Trypanosoma cruzi discrete typing units in Bolivian migrants in Spain.

José A Perez-Molina1, Cristina Poveda2, Angela Martinez-Perez3, Felipe Guhl2, Begoña Monge-Maillo3, Manuel Fresno4, Rogelio López-Velez3, Juan D Ramírez2, Nuria Girones4.   

Abstract

Chagas disease is caused by the protozoan Trypanosoma cruzi. This parasite is transmitted to humans mainly through the faeces of infected triatomine "kissing" bugs, by blood transfusions or organ donation from infected donors, and can be transmitted from mother to child. This disease is endemic in the Americas, where Bolivia has up to 28.8% prevalence in general population. Increased migration to Europe has made it emerge in countries where it was previously unknown, being Spain the second country in number of patients after the United States. T. cruzi is an organism with a rich genetic diversity, what has been grouped into six discrete typing units (DTUs). Some authors have linked these DTUs either to specific geographical distribution or to the different clinical presentations. Nevertheless little is known about its distribution in migrant populations. Our aim was to describe the T. cruzi strains isolated from a population of chronically infected Bolivian patients attending our clinic in Madrid. Thirty-three consecutive patients meeting this condition were selected for the study. Molecular characterization was performed by an algorithm that combines PCR of the intergenic region of the mini exon-gene, the 24Sα and 18S regions of rDNA and the variable region of the satellite DNA. A descriptive analysis was performed and associations between epidemiological/clinical data and the different DTUs were tested. Twenty-seven out of thirty-three patients had their DTU detected. Mean age was 36 years (IQR 31-43.3) and 23 were women (76.7%). The median time since arrival to Spain was 60 months (IQR 43-81). The most common DTU were TcV, TcIV and TcI. Four patients had cardiac involvement: 2 had TcV and 2 could not have their DTU determined. TcIII was not isolated from any patient. DTUs distribution in migrant population seems to be similar to that observed in the patients' countries of origin.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chagas disease; Discrete typing units; Migration; Trypanosoma cruzi

Mesh:

Substances:

Year:  2014        PMID: 24389118     DOI: 10.1016/j.meegid.2013.12.018

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  5 in total

1.  Oesophageal motility disorders in infected immigrants with Chagas disease in a non-endemic European area.

Authors:  Sílvia Roure; Lluís Valerio; Xavier Vallès; Betty Morales; M Immaculada Garcia-Diaz; M Luisa Pedro-Botet; Jordi Serra
Journal:  United European Gastroenterol J       Date:  2016-02-03       Impact factor: 4.623

Review 2.  Advances in preclinical approaches to Chagas disease drug discovery.

Authors:  Fernando Villalta; Girish Rachakonda
Journal:  Expert Opin Drug Discov       Date:  2019-08-14       Impact factor: 6.098

3.  Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against Trypanosoma cruzi.

Authors:  Natacha Cerny; Augusto Ernesto Bivona; Andrés Sanchez Alberti; Sebastián Nicolás Trinitario; Celina Morales; Alejandro Cardoso Landaburu; Silvia Inés Cazorla; Emilio Luis Malchiodi
Journal:  Front Immunol       Date:  2020-10-09       Impact factor: 7.561

4.  Impact of Helminth Infection on the Clinical and Microbiological Presentation of Chagas Diseases in Chronically Infected Patients.

Authors:  Fernando Salvador; Elena Sulleiro; Adrián Sánchez-Montalvá; Mónica Martínez-Gallo; Eugenia Carrillo; Israel Molina
Journal:  PLoS Negl Trop Dis       Date:  2016-04-26

Review 5.  Evolutionary ecology of Chagas disease; what do we know and what do we need?

Authors:  Alheli Flores-Ferrer; Olivier Marcou; Etienne Waleckx; Eric Dumonteil; Sébastien Gourbière
Journal:  Evol Appl       Date:  2017-12-25       Impact factor: 5.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.